Falk evening symposium on microscopic colitis
For a long time, microscopic colitis was underestimated as a disease pattern. It is now clear that – like Crohn’s disease and ulcerative colitis – it is an inflammatory bowel disease and is now included as such in the current guidelines of the European Crohn and Colitis Organisation (ECCO).
Experts of the European Microscopic Colitis Group (EMCG) spoke at a symposium organized by the Falk Foundation e.V. as part of the “United European Gastroenterology Week 2013” (UEGW 2013) in Berlin to discuss potential methods of diagnosis and therapy for this disease.
The ejournal “Treatment Strategies” covered the evening symposium in a comprehensive article (LINK: http://viewer.zmags.com/publication/69da19a6#/69da19a6/50) as well as with an in-depth interview (LINK: http://viewer.zmags.com/publication/69da19a6#/69da19a6/34) with Prof. Stephan Miehlke, the scientific organizer of the symposium.
Video
Faecal microbial transplantation in ulcerative colitis
Video report of the presentation given by Prof. Eytan Wine, University of Alberta, Canada, at the Falk Symposium 190 “Challenges in the Care of IBD in Patients of all Ages” in London, October 2 – 3, 2013. © Falk Foundation e.V., Freiburg. All rights reserved.
Summary:
Depending on an individual’s genetic predisposition, gut microbes are influenced by environmental factors, such as nutrition, hygiene or infections. They are decisive for the pathogenesis of ulcerative colitis and Crohn’s disease. An innovative, promising approach to influence gut microbes is faecal microbial transplantation, which has already been found to be successful in treating Clostridium difficile infections.
A recent study (Kunde et al., 2013) has shown that faecal microbial transplantations are also effective and safe in children and young adults with ulcerative colitis.
In this study, faecal microbial transplantations were carried out on five consecutive days in 10 patients aged between 7 and 21 with mild-to-moderate ulcerative colitis.
One participant was unable to hold the stool and was excluded from the study. 7 of the 9 patients showed a clinical response, which lasted for more than a month in 6 of the participants. Clinical remission was observed in 3 of the patients after one week. The faecal microbial transplantation was well tolerated and may become important in the future treatment of ulcerative colitis.
Please switch on your loudspeakers!
Link to Falk Mediacenter:
http://media.falkfoundation.de/index.php?id=81&L=1
Link to the video directly:
http://media.drfalkpharma.de/fileadmin/media/131209_Microbiota_e_mittel.mp4
Preview images:
180 x 117 pixels
http://www.drfalkpharma.de/fileadmin/media/Video/Microbiota_180.png
580 x 370 pixels
http://www.drfalkpharma.de/fileadmin/media/Video/Microbiota_580.png
Latest research in brief:
Description field (to be displayed at the end of the structural element):
Editor: Prof. W. Kreisel, Medical University Hospital, 79106 Freiburg, Germany
Bowel
Vajro P et al, J Pediatr Gastroenterol Nutr. 2013;56(6):663–70
Celiac disease is associated with elevated transaminase levels in about one-third of newly diagnosed children. In most cases liver involvement is normalized by gluten-free diet.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18003#c24679
###################################################################
Long MD et al, Inflamm Bowel Dis. 2013;19(5):1018–24
Although the overall risk of Pneumocystis jirovecii is low, patients with inflammatory bowel disease are at increased risk.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18003#c24680
###################################################################
Yuhara H et al, Aliment Pharmacol Ther. 2013;37(10):953–62
A meta-analysis: Inflammatory bowel disease is associated with an approximately 2-fold increase in the risk of venous thromboembolism.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18003#c24681
Liver
Biliary Tracts
Ryan MC et al, J Hepatol. 2013;59(1):138–43
Mediterranean diet reduces liver steatosis and improves insulin sensitivity in patients with non-alcoholic fatty liver disease, even without weight loss.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18003#c24682
###################################################################
Singh S et al, Inflamm Bowel Dis. 2013;19(8):1631–8
Ursodeoxycholic acid, particularly at low doses, may reduce the risk of advanced colorectal neoplasia in patients with primary sclerosing cholangitis and concomitant inflammatory bowel disease.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18003#c24683
###################################################################
Sulkowski MS et al, Hepatology. 2013;57(6):2143–54
Faldaprevir, a new hepatitis C virus NS3/4A protease inhibitor, combined with pegylated interferon-α2a and ribavirin achieved high sustained virologic response rates with acceptable tolerability and safety.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18003#c24684
###################################################################
Oesophagus
Stomach
Duodenum
Sivarasan N et al, J Dig Dis. 2013;14(5):222–30
A meta-analysis confirms: Aspirin confers a significant protective effect against esophageal adenocarcinomas.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18003#c24686
###################################################################
Gisbert JP et al, Scand J Gastroenterol. 2013;48(6):652–6
Ten-day levofloxacin-containing triple therapy is an encouraging second-line strategy in patients with previous failure of a non-bismuth sequential or concomitant quadruple therapy of H. pylori infection.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18003#c24685
###################################################################
Choi JS et al, Scand J Gastroenterol. 2013;48(6):657–62
Upper gastrointestinal evaluation is mandatory in patients with positive fecal occult blood test and negative colonoscopy. This study found in 1.2% gastric carcinomas and in 16% peptic ulcers.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18003#c24687
Pancreas
Yadav D et al, Gastroenterology. 2013;144(6):1252–61
Alcohol abstinence and smoking cessation can alter the progression of pancreatitis and reduce recurrence. Smoking cessation is the most effective strategy to reduce the risk of pancreatic cancer.
Link:
http://www.drfalkpharma.de/index.php?L=1&id=18003#c24678
Current Falk literature:
Falk Symposium report
Inflammatory Bowel Diseases: Microbiota versus the Barrier
(34 pages)
Auflage 2014
FSR188e
Picture:
http://www.drfalkpharma.de/fileadmin/media/Falk_Broschueren/Ebooks/FSR188e.jpg
PDF:
http://www.drfalkpharma.de/fileadmin/media/Falk_Broschueren/Ebooks/FSR188e_Screen.pdf
Order by email (Please replace text by your email address):